Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5127310 | 0.87 | SMN1; SMN2 (0.37) | SMN1; SMN2KMT2ARXFP1MEN1TP53 | |
| SCHEMBL5115257 | 0.87 | S1PR3 (0.43) | — | |
| SCHEMBL5129804 | 0.85 | SMN1; SMN2 (0.48) | LMNASMN1; SMN2KMT2AHTTALDH1A1 | |
| SCHEMBL5127488 | 0.81 | MAOB (0.45) | LMNASMN1; SMN2KMT2AMEN1TP53 | |
| SCHEMBL5116985 | 0.79 | CYP1A2 (0.44) | SMN1; SMN2KMT2ATP53POLBALDH1A1 | |
| SCHEMBL5139448 | 0.77 | SMN1; SMN2 (0.52) | SMN1; SMN2KMT2APOLBALDH1A1CYP1A2 | |
| SCHEMBL5128943 | 0.76 | LMNA (0.47) | LMNASMN1; SMN2KMT2ATP53HTT | |
| SCHEMBL5116009 | 0.74 | S1PR4 (0.43) | SMN1; SMN2KMT2ATP53POLBALDH1A1 | |
| SCHEMBL5122592 | 0.74 | EGLN1 (0.54) | SMN1; SMN2KMT2APOLBALDH1A1CYP1A2 | |
| SCHEMBL5114522 | 0.74 | SMN1; SMN2 (0.49) | SMN1; SMN2KMT2ARXFP1MEN1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075356-A1 | Dihydroxypyrimidine carboxamide inhibitors of hiv integrase | ISTITUTO DI RICHERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075356-A1 | Dihydroxypyrimidine carboxamide inhibitors of hiv integrase | DUT, DPYD, TYMP | LMNA 4057/4885SMN1; SMN2 4143/4885KMT2A 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.